Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
1(9%)
Results Posted
80%(8 trials)

Phase Distribution

Ph phase_3
5
45%
Ph phase_1
5
45%
Ph phase_2
1
9%

Phase Distribution

5

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
5(45.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(10)

Detailed Status

Completed10
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (45.5%)
Phase 21 (9.1%)
Phase 35 (45.5%)

Trials by Status

completed1091%
recruiting19%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_2

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

NCT02232191
completedphase_1

Extension Safety and Immunogenicity Study of GPNV-001

NCT05982314
completedphase_1

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

NCT05667740
completedphase_1

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

NCT04665050
completedphase_3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

NCT03565900
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02232191Phase 2

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Recruiting
NCT05982314Phase 1

Extension Safety and Immunogenicity Study of GPNV-001

Completed
NCT05667740Phase 1

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Completed
NCT04665050Phase 1

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

Completed
NCT03565900Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Completed
NCT03921424Phase 3

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

Completed
NCT04168190Phase 1

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Completed
NCT03480802Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Completed
NCT03480763Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Completed
NCT03547167Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Completed
NCT02543918Phase 1

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11